Family-Focused Therapy for Psychosis
Trial Summary
Do I have to stop taking my current medications for the trial?
The trial protocol does not specify whether you need to stop taking your current medications. However, you must be willing to taper individual therapy to monthly sessions by the start of treatment.
Do I need to stop taking my current medications to join the trial?
The trial information does not specify whether you need to stop taking your current medications. However, it does mention that participants must be willing to reduce individual therapy sessions to once a month by the start of treatment.
What data supports the idea that Family-Focused Therapy for Psychosis is an effective treatment?
The available research shows that Family-Focused Therapy (FFT) is effective for individuals at high risk for psychosis. One study found that FFT led to greater improvements in family communication compared to a shorter family education program. Another study showed that FFT was more effective than brief psychoeducation in reducing the severity of early psychotic symptoms over six months. Additionally, FFT has been associated with reduced mood episodes in youth at high risk for bipolar disorder, suggesting its effectiveness in improving mood and social functioning.12345
What data supports the effectiveness of the treatment Family-Focused Therapy for Psychosis?
Research shows that Family-Focused Therapy (FFT) can help improve communication and reduce symptoms in young people at high risk for psychosis. It has also been effective in reducing mood episodes in youth at high risk for bipolar disorder, suggesting its potential benefits for similar conditions.12345
What safety data exists for Family-Focused Therapy for Psychosis?
The studies reviewed do not explicitly mention safety data for Family-Focused Therapy (FFT) for psychosis. However, they suggest that FFT is effective in reducing symptoms and improving family functioning in individuals at high risk for psychosis and bipolar disorder. The therapy involves psychoeducation, communication training, and problem-solving skills, and has been compared to enhanced care (EC) and psychoeducational interventions. No adverse safety concerns are reported in these studies, indicating that FFT is generally considered safe for participants.12356
Is Family-Focused Therapy (FFT) safe for humans?
Family-Focused Therapy (FFT) has been studied in various forms and for different conditions, such as psychosis and bipolar disorder, and no safety concerns have been reported in these studies. It involves psychoeducation, communication training, and problem-solving skills, which are generally considered safe for participants.12356
Is Family Focused Therapy a promising treatment for young people at high risk of psychosis?
Yes, Family Focused Therapy (FFT) is a promising treatment for young people at high risk of psychosis. Research shows that FFT helps reduce the severity of early psychotic symptoms and improves family communication. It is more effective than basic education alone and can be implemented efficiently with community clinicians.23457
How is Family Focused Therapy for Clinical High Risk Youth (FFT-CHR) different from other treatments for psychosis?
Family Focused Therapy for Clinical High Risk Youth (FFT-CHR) is unique because it combines psychoeducation, communication training, and problem-solving skills in an 18-session format, which has been shown to improve family communication and reduce symptoms more effectively than brief psychoeducation alone for those at high risk of psychosis.23457
What is the purpose of this trial?
The present study is a confirmatory efficacy trial of Family Focused Therapy for youth at clinical high risk for psychosis (FFT-CHR). This trial is sponsored by seven mature CHR clinical research programs from the North American Prodrome Longitudinal Study (NAPLS). The young clinical high risk sample (N = 220 youth ages 13-25) is to be followed at 6-month intervals for 18 months.
Research Team
David J Miklowitz, Ph.D.
Principal Investigator
University of California, Los Angeles
Kristin Cadenhead, MD
Principal Investigator
University of California, San Diego
Scott Woods, MD
Principal Investigator
Yale University
Jean Addington, Ph.D.
Principal Investigator
University of Calgary
Andrea M. Auther, Ph.D.
Principal Investigator
Zucker Hillside Hospital at Hofstra / Northwell Health
Barbara A. Cornblatt, Ph.D., M.B.A.
Principal Investigator
Hofstra University / Northwell Health
Daniel Mathalon, MD
Principal Investigator
University of California, San Francisco
Holly K. Hamilton, Ph.D.
Principal Investigator
University of California, San Francisco
Carrie E. Bearden, Ph.D.
Principal Investigator
University of California, Los Angeles
Michelle Friedman-Yakoobian, Ph.D.
Principal Investigator
Harvard Medical School/Massachusetts Mental Health Center
Eligibility Criteria
This trial is for English-speaking youth aged 13-25 at high risk for psychosis, who have a parent or guardian involved in their life and can consent to treatment. Participants must show early signs of psychosis but cannot have a full psychotic disorder, severe substance abuse issues, or intellectual impairment.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Family Focused Therapy (FFT-CHR) or Enhanced Care (EC) for 6 months, including family and individual sessions
Follow-up
Participants are monitored for safety and effectiveness after treatment, with assessments at 6-month intervals
Treatment Details
Interventions
- Enhanced Care (EC)
- Family Focused Therapy for Clinical High Risk Youth (FFT-CHR)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, Los Angeles
Lead Sponsor
National Institute of Mental Health (NIMH)
Collaborator